The price of Titan Pharmaceuticals Inc. (NASDAQ:TTNP) shares last traded on Wall Street rose 2.00% to $1.02.
Based on available information, 1 analysts follow Titan Pharmaceuticals Inc. (NASDAQ:TTNP). The consensus rating among analysts is ‘Hold’. As we calculate the median target price by taking the range between a high of $7.00 and a low of $7.00, we find $7.00. Given the previous closing price of $1.00, this indicates a potential upside of 600.0 percent. TTNP stock price is now 13.79% away from the 50-day moving average and 6.94% away from the 200-day moving average. The market capitalization of the company currently stands at $14.47M.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
Among analysts, 1 rate the stock a hold while 0 rate it a buy. Brokers who have rated the stock have averaged $7.00 as their price target over the next twelve months.
With the price target of $4, Maxim Group recently initiated with Buy rating for Titan Pharmaceuticals Inc. (NASDAQ: TTNP).
In other news, Lazar David E., Chief Executive Officer bought 20,000 shares of the company’s stock on Jan 25. The stock was bought for $20,066 at an average price of $1.00. Upon completion of the transaction, the Chief Executive Officer now directly owns 3,388,902 shares in the company, valued at $3.46 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Jan 24, Chief Executive Officer Lazar David E. bought 37,500 shares of the business’s stock. A total of $36,221 was incurred on buying the stock at an average price of $0.97. This leaves the insider owning 3,368,902 shares of the company worth $3.44 million. A total of 25.62% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in TTNP stock. A new stake in Titan Pharmaceuticals Inc. shares was purchased by TRUIST FINANCIAL CORP during the first quarter worth $638,000. STATE STREET CORP invested $39,000 in shares of TTNP during the first quarter. In the first quarter, CITADEL ADVISORS LLC acquired a new stake in Titan Pharmaceuticals Inc. valued at approximately $13,000. In total, there are 25 active investors with 10.60% ownership of the company’s stock.
A candlestick chart of Titan Pharmaceuticals Inc. (NASDAQ: TTNP) showed a price of $1.0300 on Thursday morning. During the past 12 months, Titan Pharmaceuticals Inc. has had a low of $0.35 and a high of $1.59. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 2.20, and a quick ratio of 2.00. The fifty day moving average price for TTNP is $0.8986 and a two-hundred day moving average price translates $0.9548 for the stock.
The latest earnings results from Titan Pharmaceuticals Inc. (NASDAQ: TTNP) was released for Jun, 2022. According to the Biotechnology Company, earnings per share came in at -$0.19, beating analysts’ expectations of -$0.35 by 0.16. This compares to -$0.19 EPS in the same period last year. The company reported revenue of $95000.0 for the quarter, compared to $0.26 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -64.02 percent. For the current quarter, analysts expect TTNP to generate $135k in revenue.
Titan Pharmaceuticals Inc.(TTNP) Company Profile
Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases. It develops products based on ProNeura, a proprietary long-term drug delivery platform. The company offers Probuphine implant for the maintenance treatment of opioid use disorder in clinically stable patients in Canada and the European Union. It is also developing kappa opioid agonist peptide program (TP-2021) for use in combination with ProNeura technology for the treatment of chronic pruritus; nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder; and other programs, including HIV preventative therapeutic and a contraceptive from a single ProNeura implant for women and adolescent girls. The company was incorporated in 1992 and is based in South San Francisco, California.
Leave a Reply